½ÃÀ庸°í¼­
»óǰÄÚµå
1305188

¼¼°èÀÇ HIV/AIDS Áø´Ü ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2023-2030³â)

Global HIV/AIDS Diagnostics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 156 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

HIV/AIDS Áø´Ü ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â 2022³â 62¾ï 2,000¸¸ ´Þ·¯¿¡¼­ 2030³â 137¾ï 5,000¸¸ ´Þ·¯¿¡ °¡±î¿î ½ÃÀå ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, 2023-2030³â Á¶»ç ±â°£ µ¿¾È 10.42%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

HIV/AIDS Áø´ÜÀº Àΰ£¸é¿ª°áÇ̹ÙÀÌ·¯½º(HIV)ÀÇ Á¸À縦 °¨ÁöÇϰí ÈÄõ¼º¸é¿ª°áÇÌÁõÈıº(AIDS)ÀÇ ÁøÇàÀ» ¸ð´ÏÅ͸µÇÏ´Â µ¥ »ç¿ëµÇ´Â °Ë»ç ¹× ¹æ¹ýÀ» ¸»ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Áø´Ü¿¡´Â HIV Ç×ü ¹× Ç׿ø, ¹ÙÀÌ·¯½º ¾ç, CD4 T ¼¼Æ÷ ¼ö¸¦ °¨ÁöÇÒ ¼ö ÀÖ´Â ´Ù¾çÇÑ ½ÇÇè½Ç °Ë»ç ¹× ÇöÀå °Ë»ç(POC) Àåºñ°¡ Æ÷ÇԵ˴ϴÙ.

½ÃÀå ¿ªÇÐ:

HIV/AIDS ¿¹¹æ ¹× Ä¡·áÀÇ Å« ÁøÀü¿¡µµ ºÒ±¸Çϰí, ÀÌ Áúº´Àº ¿©ÀüÈ÷ ¼¼°è º¸°ÇÀÇ Å« µµÀüÀÌ µÇ°í ÀÖÀ¸¸ç, 2019³â¿¡´Â Àü ¼¼°èÀûÀ¸·Î ¾à 3,800¸¸ ¸íÀÌ HIV/AIDS¸¦ ¾Î°í ÀÖ´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù(WHO º¸°í¼­). ÀÌ·¯ÇÑ HIV/AIDSÀÇ ³ôÀº À¯º´·üÀº Áúº´À» Á¤È®ÇÏ°Ô °¨ÁöÇÏ°í ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ´Â Áø´Ü¾à¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÁßÀú¼Òµæ ±¹°¡¿¡¼­ ÀÇ·á ½Ã½ºÅÛÀÌ °³¼±µÇ°í Á¢±Ù¼ºÀÌ ³ô¾ÆÁü¿¡ µû¶ó HIV/AIDS °Ë»ç¸¦ ¹Þ´Â »ç¶÷µéÀÌ ´Ã¾î³ª°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó Àú·ÅÇϰí Á¤È®ÇÏ¸ç »ç¿ëÇϱ⠽¬¿î Áø´Ü °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÃÖ±Ù Áø´Ü ±â¼úÀÇ ¹ßÀüÀ¸·Î HIV/AIDS¿¡ ´ëÇÑ º¸´Ù ¹Î°¨ÇÏ°í Æ¯ÀÌÀûÀÎ °Ë»ç¹ýÀÌ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, »õ·Î¿î POC Àåºñ´Â ³ôÀº Á¤È®µµ¿Í ºü¸¥ °á°ú¸¦ Á¦°øÇÏ¿© Á¶±â Áø´Ü ¹× Á¶±â Ä¡·á¸¦ °¡´ÉÇÏ°Ô Çϸç, HIV/AIDS ÀÚ°¡ °Ë»ç´Â ƯÈ÷ HIV/AIDSÀÇ À¯º´·üÀÌ ³ôÀº ±¹°¡¿¡¼­ ³Î¸® º¸±ÞµÇ°í ÀÖ½À´Ï´Ù. ÀÚ°¡ °Ë»ç´Â ÀÇ·á ¼­ºñ½º Á¦°øÀÚ¸¦ ÅëÇÏÁö ¾Ê°í Áý¿¡¼­ ÇÁ¶óÀ̹ö½Ã¸¦ ÁöŰ¸é¼­ ½º½º·Î °Ë»çÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÚ°¡ °Ë»ç ŰƮ´Â Á¤È®Çϰí Àú·ÅÇÏ¸ç »ç¿ëÇϱ⠽±±â ¶§¹®¿¡ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¤ºÎ¿Í ±¹Á¦±â±¸´Â HIV/AIDSÀÇ Áø´Ü°ú Ä¡·á¸¦ °³¼±Çϱâ À§ÇÑ ³ë·Â¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¿©±â¿¡´Â »õ·Î¿î Áø´Ü ±â¼ú ¿¬±¸ ¹× °³¹ß ÀÚ±Ý Áö¿ø, °Ë»ç ¹× Ä¡·á Á¢±Ù¼º Çâ»óÀ» À§ÇÑ ÇÁ·Î±×·¥ µîÀÌ Æ÷ÇԵ˴ϴÙ.

ÀÌ Á¶»ç º¸°í¼­´Â Porter's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Âµµ ºÐ¼® ¹× ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ì´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â ¾÷°èÀÇ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØ¿¡¼­ °æÀïÀÇ ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀ̵˴ϴÙ. ¶ÇÇÑ ÀÌ·¯ÇÑ µµ±¸´Â HIV/AIDS Áø´Ü ¼¼°è ½ÃÀå¿¡¼­ °¢ ºÎ¹®À» Æ÷°ýÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖÀ¸¸ç, HIV/AIDS Áø´Ü »ê¾÷ÀÇ ¼ºÀå°ú Ãß¼¼´ÂÀÌ ¿¬±¸¿¡ ´ëÇÑ ÀüüÀûÀÎ Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­:

ÀÌ ¼½¼Ç¿¡¼­´Â ±¹°¡º°, Áö¿ªº° ºÎ¹®¿¡ ´ëÇÑ »ó¼¼ÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© °¢ Á¦Ç° ¹× ¼­ºñ½ºÀÇ Å¸°ÙÃþÀ» ÆÄ¾ÇÇÏ¿© ÇâÈÄ ºñÁö´Ï½º ±âȸ¸¦ âÃâÇÒ ¼ö ÀÖµµ·Ï µµ¿Íµå¸³´Ï´Ù.

Á¦Ç°º°

  • ŰƮ ¹× ½Ã¾à
  • °Ë»ç Àåºñ

°Ë»ç À¯Çüº°

  • ÇÙ»ê °Ë»ç
  • ºü¸¥ °Ë»ç(POC)
  • ELISA °Ë»ç
  • ±âŸ

ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
  • Áø´Ü¿¬±¸¼Ò
  • Çмú¿¬±¸±â°ü
  • ±âŸ

Áö¿ªº° ºÐ¼®

ÀÌ ¼½¼Ç¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ HIV/AIDS Áø´Ü ½ÃÀåÀÇ ÇöÀç ¹× ¹Ì·¡ ¼ö¿ä¸¦ °­Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ, ¸ðµç ÁÖ¿ä Áö¿ªÀÇ °³º° ¾ÖÇø®ÄÉÀÌ¼Ç ºÎ¹®ÀÇ ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀå ÇöȲ

Á¦3Àå HIV/AIDS Áø´Ü - »ê¾÷ ºÐ¼®

  • ¼­·Ð : ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • ¾÷°è µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀå ¸Å·Âµµ ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀç·á ºÐ¼®
    • ¿øÀç·á ¸®½ºÆ®
    • ¿øÀç·á Á¦Á¶¾÷ü ¸®½ºÆ®
    • ÁÖ¿ä ¿øÀç·á °¡°Ý µ¿Çâ
  • ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
  • ¸¶ÄÉÆÃ Ã¤³Î
    • Á÷Á¢ ¸¶ÄÉÆÃ
    • °£Á¢ ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ

Á¦5Àå COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå HIV/AIDS Áø´Ü ¼¼°è ½ÃÀå ºÐ¼® : Á¦Ç°º°

  • Á¦Ç°º° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • Á¦Ç°º° ºÐ¼®
  • ŰƮ ¹× ½Ã¾à
  • °Ë»ç ±â±â

Á¦7Àå HIV/AIDS Áø´Ü ¼¼°è ½ÃÀå ºÐ¼® : °Ë»ç À¯Çüº°

  • °Ë»ç À¯Çüº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • °Ë»ç À¯Çüº° ºÐ¼®
  • ÇÙ»ê °Ë»ç
  • ½Å¼Ó °Ë»ç(POC)
  • ELISA °Ë»ç
  • ±âŸ

Á¦8Àå HIV/AIDS Áø´Ü ¼¼°è ½ÃÀå ¸ÅÃ⠺м® : ÃÖÁ¾»ç¿ëÀÚº°

  • ÃÖÁ¾»ç¿ëÀÚº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • ÃÖÁ¾»ç¿ëÀÚº° ºÐ¼®
  • º´¿ø
  • Áø´Ü ¿¬±¸¼Ò
  • Çмú¿¬±¸±â°ü
  • ±âŸ

Á¦9Àå HIV/AIDS Áø´Ü ¼¼°è ½ÃÀå ¸ÅÃ⠺м® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á ¸ÅÃ⠺м®
  • ¼­·Ð ¸ÅÃ⠺м®
  • ºÏ¹ÌÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì : ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • À¯·´ : ºÎ¹®º°
    • À¯·´ : ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä« ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º°
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå HIV/AIDS Áø´Ü ±â¾÷ °æÀï »óȲ

  • HIV/AIDS Áø´Ü ½ÃÀå °æÀï
  • Á¦ÈÞ, Çù·Â, ÇÕÀÇ
  • ÀμöÇÕº´
  • ½ÅÁ¦Ç° Ãâ½Ã
  • ±âŸ °³¹ß

Á¦11Àå ±â¾÷ °³¿ä

  • »óÀ§ 10°³»ç Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • Hologic Inc.
  • Abbott
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche Ltd.
  • OraSure Technologies Inc.
  • Siemens Healthcare GmbH
  • Chembio Diagnostics Inc.
  • Danaher Corporation
  • Becton
  • Dickinson and Company

*Âü°í : ±â¾÷ °³¿ä¿¡¼­ À繫 ³»¿ëÀ̳ª ÃÖ±ÙÀÇ µ¿ÇâÀº ºñ°ø°³ ±â¾÷ÀÇ °æ¿ì ÀÔ¼ö °¡´É ¿©ºÎ¿¡ µû¶ó ´Þ¶óÁö°Å³ª Á¦°øµÇÁö ¾ÊÀ» ¼ö ÀÖ½À´Ï´Ù.

ksm 23.08.22

The global demand for HIV/AIDS Diagnostics Market is presumed to reach the market size of nearly USD 13.75 BN by 2030 from USD 6.22 BN in 2022 with a CAGR of 10.42% under the study period 2023 - 2030.

HIV/AIDS diagnostics refer to the tests and methods used to detect the presence of the human immunodeficiency virus (HIV) and monitor the progression of acquired immunodeficiency syndrome (AIDS). These diagnostics include various laboratory tests and point-of-care (POC) devices that can detect HIV antibodies or antigens, viral load, and CD4 T-cell count.

Market Dynamics:

Despite significant progress in HIV/AIDS prevention and treatment, the disease remains a major global health challenge. There were an estimated 38 million people living with HIV/AIDS worldwide in 2019 (WHO report). This high prevalence of HIV/AIDS is driving the demand for diagnostics that can accurately detect and monitor the disease. As healthcare systems improve and become more accessible in low- and middle-income countries, more people are being tested for HIV/AIDS. This is leading to a greater demand for affordable, accurate, and easy-to-use diagnostic tests. Recent advancements in diagnostic technology have led to the development of more sensitive and specific tests for HIV/AIDS. For example, new POC devices can deliver rapid results with high accuracy, allowing for earlier diagnosis and treatment. Self-testing for HIV/AIDS is becoming more popular, particularly in countries with high HIV/AIDS prevalence. Self-testing allows individuals to test themselves in the privacy of their own home, without the need for a healthcare provider. This has scaled up self-testing kits demand as they are accurate, affordable, and easy to use. Governments and international organizations are investing in initiatives to improve HIV/AIDS diagnosis and treatment. This includes funding for research and development of new diagnostic technologies, as well as programs to increase access to testing and treatment.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of hiv/aids diagnostics. The growth and trends of hiv/aids diagnostics industry provide a holistic approach to this study.

Market Segmentation:

This section of the hiv/aids diagnostics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

  • Kits And Reagents
  • Instruments

By Test Type

  • Nucleic Acid Tests
  • Rapid Tests (POC)
  • ELISA
  • Others

By End-User

  • Hospitals
  • Diagnostic Laboratories
  • Academic And Research Institutes
  • Others

Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the HIV/AIDS Diagnostics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the hiv/aids diagnostics market include Hologic Inc., Abbott, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., OraSure Technologies Inc., Siemens Healthcare GmbH, Chembio Diagnostics Inc., Danaher Corporation, Becton, Dickinson and Company. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . HIV/AIDS DIAGNOSTICS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Product
    • 3.7.2 Market Attractiveness Analysis By Test Type
    • 3.7.3 Market Attractiveness Analysis By End-user
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL HIV/AIDS DIAGNOSTICS MARKET ANALYSIS BY PRODUCT

  • 6.1 Overview by Product
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Product
  • 6.4 Kits And Reagents Historic and Forecast Sales by Regions
  • 6.5 Instruments Historic and Forecast Sales by Regions

7 . GLOBAL HIV/AIDS DIAGNOSTICS MARKET ANALYSIS BY TEST TYPE

  • 7.1 Overview by Test Type
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Test Type
  • 7.4 Nucleic Acid Tests Historic and Forecast Sales by Regions
  • 7.5 Rapid Tests (POC) Historic and Forecast Sales by Regions
  • 7.6 ELISA Historic and Forecast Sales by Regions
  • 7.7 Others Historic and Forecast Sales by Regions

8 . GLOBAL HIV/AIDS DIAGNOSTICS MARKET SALES ANALYSIS BY END-USER

  • 8.1 Overview by End-user
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by End-user
  • 8.4 Hospitals Historic and Forecast Sales by Regions
  • 8.5 Diagnostic Laboratories Historic and Forecast Sales by Regions
  • 8.6 Academic And Research Institutes Historic and Forecast Sales by Regions
  • 8.7 Others Historic and Forecast Sales by Regions

9 . GLOBAL HIV/AIDS DIAGNOSTICS MARKET SALES ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook Sales Analysis
  • 9.2. Introduction Sales Analysis
  • 9.3. North America Sales Analysis
    • 9.3.1. Overview, Historic and Forecast Sales Analysis
    • 9.3.2. North America By Segment Sales Analysis
    • 9.3.3. North America By Country Sales Analysis
    • 9.3.4. United State Sales Analysis
    • 9.3.5. Canada Sales Analysis
    • 9.3.6. Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1. Overview, Historic and Forecast Sales Analysis
    • 9.4.2. Europe by Segment Sales Analysis
    • 9.4.3. Europe by Country Sales Analysis
    • 9.4.4. United Kingdom Sales Analysis
    • 9.4.5. France Sales Analysis
    • 9.4.6. Germany Sales Analysis
    • 9.4.7. Italy Sales Analysis
    • 9.4.8. Russia Sales Analysis
    • 9.4.9. Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1. Overview, Historic and Forecast Sales Analysis
    • 9.5.2. Asia Pacific by Segment Sales Analysis
    • 9.5.3. Asia Pacific by Country Sales Analysis
    • 9.5.4. China Sales Analysis
    • 9.5.5. India Sales Analysis
    • 9.5.6. Japan Sales Analysis
    • 9.5.7. South Korea Sales Analysis
    • 9.5.8. Australia Sales Analysis
    • 9.5.9. Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1. Overview, Historic and Forecast Sales Analysis
    • 9.6.2. Latin America by Segment Sales Analysis
    • 9.6.3. Latin America by Country Sales Analysis
    • 9.6.4. Brazil Sales Analysis
    • 9.6.5. Argentina Sales Analysis
    • 9.6.6. Peru Sales Analysis
    • 9.6.7. Chile Sales Analysis
    • 9.6.8. Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1. Overview, Historic and Forecast Sales Analysis
    • 9.7.2. Middle East & Africa by Segment Sales Analysis
    • 9.7.3. Middle East & Africa by Country Sales Analysis
    • 9.7.4. Saudi Arabia Sales Analysis
    • 9.7.5. UAE Sales Analysis
    • 9.7.6. Israel Sales Analysis
    • 9.7.7. South Africa Sales Analysis
    • 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE HIV/AIDS DIAGNOSTICS COMPANIES

  • 10.1. Hiv/Aids Diagnostics Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11 . COMPANY PROFILES OF HIV/AIDS DIAGNOSTICS INDUSTRY

  • 11.1. Top 10  Company Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Hologic Inc.
    • 11.3.1. Company Overview
    • 11.3.2. Company Revenue
    • 11.3.3. Products
    • 11.3.4. Recent Developments
  • 11.4. Abbott
    • 11.4.1. Company Overview
    • 11.4.2. Company Revenue
    • 11.4.3. Products
    • 11.4.4. Recent Developments
  • 11.5. Bio-Rad Laboratories Inc.
    • 11.5.1. Company Overview
    • 11.5.2. Company Revenue
    • 11.5.3. Products
    • 11.5.4. Recent Developments
  • 11.6. F. Hoffmann-La Roche Ltd.
    • 11.6.1. Company Overview
    • 11.6.2. Company Revenue
    • 11.6.3. Products
    • 11.6.4. Recent Developments
  • 11.7. OraSure Technologies Inc.
    • 11.7.1. Company Overview
    • 11.7.2. Company Revenue
    • 11.7.3. Products
    • 11.7.4. Recent Developments
  • 11.8. Siemens Healthcare GmbH
    • 11.8.1. Company Overview
    • 11.8.2. Company Revenue
    • 11.8.3. Products
    • 11.8.4. Recent Developments
  • 11.9. Chembio Diagnostics Inc.
    • 11.9.1. Company Overview
    • 11.9.2. Company Revenue
    • 11.9.3. Products
    • 11.9.4. Recent Developments
  • 11.10. Danaher Corporation
    • 11.10.1. Company Overview
    • 11.10.2. Company Revenue
    • 11.10.3. Products
    • 11.10.4. Recent Developments
  • 11.11. Becton
    • 11.11.1. Company Overview
    • 11.11.2. Company Revenue
    • 11.11.3. Products
    • 11.11.4. Recent Developments
  • 11.12. Dickinson and Company
    • 11.12.1. Company Overview
    • 11.12.2. Company Revenue
    • 11.12.3. Products
    • 11.12.4. Recent Developments

 *Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦